Literature DB >> 1469622

Potassium channel openers dilate large epicardial coronary arteries in conscious dogs by an indirect, endothelium-dependent mechanism.

C D la Rochelle1, V Richard, J L Dubois-Randé, E Roupie, J F Giudicelli, L Hittinger, A Berdeaux.   

Abstract

Cromakalim and pinacidil, two potassium channel openers, dilate both large and small coronary arteries in conscious dogs. Because flow-mediated dilation of large arteries is endothelium-dependent, the consequences of in vivo endothelium removal (balloon denudation) on the response of large epicardial coronary arteries to cromakalim (10 micrograms/kg) and pinacidil (30 micrograms/kg) were investigated in six dogs chronically instrumented for the measurement of arterial pressure, left circumflex coronary artery diameter and coronary blood flow. Endothelium removal abolished the dilation of large coronary arteries induced by acetylcholine (endothelium-dependent dilation) and reactive hyperemia (flow-mediated dilation), but only slightly reduced (-18%) that induced by nitroglycerin. Before endothelium removal, both cromakalim and pinacidil induced a significant decrease in coronary resistance (-71 +/- 2 and -63 +/- 2%, respectively) and a significant increase in coronary diameter (8.5 +/- 1.3 and 6.7 +/- 0.9%). After endothelium removal, the decreases in coronary resistance were unaffected, but the increases in coronary diameter were reduced by 93 and 98% as compared to predenudation responses with cromakalim and pinacidil, respectively (both P < .01). In contrast, in vitro studies performed in isolated large epicardial coronary arteries obtained from five additional dogs showed that cromakalim evoked relaxations that were not affected by prior in vivo endothelium removal. Thus, despite the presence of potassium channels in isolated denuded large coronary arteries, our data demonstrate that cromakalim- and pinacidil-induced dilation of large arteries in vivo is an indirect, flow-mediated effect which is entirely endothelium-dependent.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1469622

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Influence of the endothelium, nitric oxide and serotonergic receptors on coronary vasomotor responses evoked by ergonovine in conscious dogs.

Authors:  D Karila-Cohen; E Delpy; J L Dubois-Randé; L Puybasset; L Hittinger; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

3.  Comparative effects of frovatriptan and sumatriptan on coronary and internal carotid vascular haemodynamics in conscious dogs.

Authors:  I Carel; B Ghaleh; A Edouard; J L Dubois-Rande; A A Parsons; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

4.  Vasodilator effects of sodium nitroprusside, levcromakalim and their combination in isolated rat aorta.

Authors:  F Pérez-Vizcaíno; A L Cogolludo; F Zaragozá-Arnáez; S Fajardo; M Ibarra; J G López-López; J Tamargo
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

5.  Lack of importance of NO in beta-adrenoceptor-mediated relaxation of large epicardial canine coronary arteries.

Authors:  M L Béa; B Ghaleh; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Sumatriptan-induced saphenous venoconstriction in the anaesthetized dog through 5-HT1-like receptor activation.

Authors:  C Drieu la Rochelle; S E O'Connor
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

7.  Comparisons of the effects of nicorandil, pinacidil, nicardipine and nitroglycerin on coronary vessels in the conscious dog: role of the endothelium.

Authors:  B Ghaleh; J L Dubois-Randé; L Hittinger; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.